2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights

In this study, different assortments of 2-arylquinolines and 2,6-diarylquinolines have been developed. Recently, we have developed a new series of 6,7-dimethoxy-4-alkoxy-2-arylquinolines as Topoisomerase I (TOP1) inhibitors with potent anticancer activity. Utilising the SAR outputs from this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbadawi, Mostafa M., Eldehna, Wagdy M., Abd El-Hafeez, Amer Ali, Somaa, Warda R., Albohy, Amgad, Al-Rashood, Sara T., Agama, Keli K., Elkaeed, Eslam B., Ghosh, Pradipta, Pommier, Yves, Abe, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725837/
https://www.ncbi.nlm.nih.gov/pubmed/34923887
http://dx.doi.org/10.1080/14756366.2021.2015344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725837/
https://www.ncbi.nlm.nih.gov/pubmed/34923887
http://dx.doi.org/10.1080/14756366.2021.2015344

Ejemplares similares